Teladoc (NYSE:TDOC) shares hit a new 52-week high and low during trading on Monday . The stock traded as low as $50.60 and last traded at $49.95, with a volume of 297382 shares traded. The stock had previously closed at $49.35.
Several research analysts have recently commented on TDOC shares. ValuEngine raised Teladoc from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Cantor Fitzgerald reissued a “hold” rating and issued a $35.00 target price (up from $31.00) on shares of Teladoc in a report on Tuesday, February 27th. Deutsche Bank boosted their target price on Teladoc to $45.00 and gave the stock a “buy” rating in a report on Friday, March 2nd. Canaccord Genuity upped their price objective on Teladoc from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, SunTrust Banks upped their price objective on Teladoc to $48.00 and gave the stock a “positive” rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $42.67.
The stock has a market cap of $3.08 billion, a P/E ratio of -30.24 and a beta of 0.35. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.15 and a current ratio of 4.15.
Teladoc (NYSE:TDOC) last issued its earnings results on Tuesday, May 1st. The health services provider reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.04. The company had revenue of $89.64 million during the quarter, compared to analysts’ expectations of $86.77 million. Teladoc had a negative net margin of 41.06% and a negative return on equity of 20.40%. The business’s revenue for the quarter was up 109.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.30) EPS. equities analysts expect that Teladoc will post -1.37 earnings per share for the current year.
In related news, insider Adam C. Vandervoort sold 47,123 shares of the company’s stock in a transaction on Monday, March 5th. The shares were sold at an average price of $39.36, for a total value of $1,854,761.28. Following the completion of the sale, the insider now owns 19,338 shares in the company, valued at approximately $761,143.68. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Mark Hirschhorn sold 100,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $39.60, for a total transaction of $3,960,000.00. Following the completion of the sale, the chief financial officer now owns 98,960 shares of the company’s stock, valued at approximately $3,918,816. The disclosure for this sale can be found here. Insiders have sold a total of 483,954 shares of company stock valued at $19,960,682 in the last quarter. Corporate insiders own 3.95% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in TDOC. California Public Employees Retirement System increased its position in shares of Teladoc by 52.1% in the 3rd quarter. California Public Employees Retirement System now owns 11,409 shares of the health services provider’s stock valued at $378,000 after buying an additional 3,909 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Teladoc by 12.6% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 249,789 shares of the health services provider’s stock valued at $8,706,000 after buying an additional 28,038 shares in the last quarter. Strs Ohio increased its position in shares of Teladoc by 33.3% in the 4th quarter. Strs Ohio now owns 304,226 shares of the health services provider’s stock valued at $10,602,000 after buying an additional 76,057 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Teladoc in the 4th quarter valued at $101,000. Finally, Riverbridge Partners LLC increased its position in shares of Teladoc by 44.1% in the 4th quarter. Riverbridge Partners LLC now owns 859,018 shares of the health services provider’s stock valued at $29,937,000 after buying an additional 262,959 shares in the last quarter.
Teladoc Company Profile
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.